10 results about "Progestin" patented technology

This invention discloses the application of ethinylestradiol and drospirenone in the preparation of drugs for treating post-traumatic stress disorder (PTSD). Ethinylestradiol, as an estrogen receptor agonist, regulates the hypothalamic-pituitary-gonadal axis and is used to treat female hypogonadism, menopausal syndrome, and advanced breast cancer, often in combination with progestins as oral contraceptives. The use of drospirenone and ethinylestradiol tablets (II) after induced abortion can shorten vaginal bleeding time, promote endometrial repair, and reduce the incidence of postoperative complications and repeat miscarriages. This invention has found that ethinylestradiol and drospirenone can reverse the abnormal decrease in hormones and neurosteroids caused by PTSD after spontaneous abortion, particularly the abnormal decrease in serotonin and tetrahydroprogesterone.

The present disclosure relates to a specific combination of a progestin and testosterone in a transdermal composition and usage thereof in a method for ensuring male contraception with more efficacy and less side effects.

This utility model discloses a prostaglandin vaginal capsule forming machine, relating to the technical field of capsule forming machines. It includes a support plate, with a slurry forming machine for producing prostaglandin vaginal capsules mounted on the top rear end of the support plate. The slurry forming machine has external auxiliary components for cutting. These auxiliary components include a mounting bracket mounted on the support plate, located at the front of the slurry forming machine. This utility model uses a dual-axis motor to drive a movable bracket, which is limited by a positioning bracket. The movable bracket then drives a cutter to cut the capsule. Because the unloading plate and the cutter move in contact, the slurry adhering to the cutter is pushed off by the unloading plate. Furthermore, because the unloading plate is supported by a telescopic rod and a spring, it can slowly push the slurry, avoiding excessive pressure that could scatter the slurry or hinder subsequent capsule forming. This prevents the slurry from adhering to the outside of the cutter, thus avoiding affecting the feeding efficiency and cutting effect.

The present disclosure relates to a specific combination of a progestin and testosterone in a transdermal composition and usage thereof in a method for ensuring male contraception with more efficacy and less side effects.

1. The name of the design product: packing box (progestin soft capsule). 2. The use of the design product: the design product is used for packing of goods. 3. The design points of the design product: the combination of shape and pattern. 4. The picture or photo that best shows the design points: perspective view.

1. A drug delivery device for use in treating one or more menopausal symptoms in a subject, comprising intravaginal insertion of an indwelling drug delivery device into the subject, wherein the drug delivery device comprises an estrogen and a progestin, and further provides a baseline-adjusted steady-state plasma estrogen concentration in the subject of about 15 pg / mL to about 50 pg / mL.

The invention provides a pharmaceutical composition and application thereof in treatment of endometrial cancer, and relates to the technical field of biological medicine. It is found for the first time that combined use of the KDM1A inhibitor SP-2577 and MPA has a remarkable enhancement effect on inhibition of proliferation and cloning of endometrial cancer cells and promotion of cell apoptosis, and the KDM1A inhibitor SP-2577 and the MPA have a synergistic effect; meanwhile, an in-vivo experiment result further shows that compared with independent medication of MPA or SP-2577, combined use of the KDM1A inhibitor SP-2577 and MPA has more outstanding advantages in the aspect of inhibiting tumor growth. The invention provides the pharmaceutical composition consisting of the KDM1A inhibitor SP-2577 and the MPA, the pharmaceutical composition effectively improves the effect of treating the endometrial cancer by single progestational hormone, and an effective solution is provided for patients with low endometrial cancer progestational hormone sensitivity.

The invention discloses a group of isoprostaglandin metabolite markers for diagnosing male offspring reproductive function damage caused by exposure of nano-plastics during pregnancy and application of the isoprostaglandin metabolite markers. According to the present invention, it is found that after the parental generation is exposed to the nanometer plastic, the expression level of the prostate hormone metabolism marker 8-iso PGF3 [alpha] and / or 8-is-13, 14-dihydro-15-keto-PGF2 [alpha] related to reproductive injury in the male offspring is significantly up-regulated; therefore, 8-iso PGF3 alpha and / or 8-iso-13, 14-dihydro-15-keto-PGF2 alpha are / is taken as the metabolic marker, the influence of the male offspring reproductive injury caused by the nano plastic is disclosed, and a method is provided for diagnosis and evaluation of the male offspring reproductive injury caused by the nano plastic.

An HPC composition and method of treatment for the prevention of PTB and improved neonatal outcomes. The invention provides for a dosing regimen beginning as early as 14 weeks of fetal gestation and dosing regimens of a duration of as much as 25 weeks. The invention provides a high level of exogeneous progestin to endogenous progesterone when it is most needed. The instant invention consistently achieves active levels of HPC which achieve effectiveness. Exemplary dosing regimens comprise an oral administration of HPC in the range of 1,200 mg to 1600 mg, wherein the HPC is administered via a once a day, twice a day, or three times a day administration.

To provide novel antagonists for progestin membrane receptors. [Solution] A compound represented by the following formula (A) or a salt thereof. TIFF2026089212000015.tif41149